Tislelizumab Plus BGB-A1217 Versus Tislelizumab Versus Durvalumab When Co-administered With Concurrent Chemoradiotherapy (cCRT) in Lung Cancer – Beigene

⟵ Back to Search Results

Tislelizumab Plus BGB-A1217 Versus Tislelizumab Versus Durvalumab When Co-administered With Concurrent Chemoradiotherapy (cCRT) in Lung Cancer

Beigene Study ID

BGB-A317-A1217-301

ClinicalTrials.gov ID

NCT04866017

EudraCT Number

2020-004656-14

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

No Study Documents